Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodevelopmental and Oncological Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PCDHA4 drug discovery. The protein comprises three cadherin domains (UniProt Q9UN74) and harbors clinically relevant polymorphisms (rs11167605, rs3822346), which may influence binding specificity. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PCDHA4 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed for native glycosylation of cadherin repeats. |
View PCDHA4 Products |
| Gene Delivery | PCDHA4 Promise-ORF Lentivirus Full-length human PCDHA4 ORF for stable cell line generation. Preserves native surface conformation. |
View PCDHA4 Products |
| Benchmark Ab | Anti-PCDHA4 Recombinant Antibody Rabbit monoclonal positive control. Sequence Verified. |
View PCDHA4 Products |
| Validator | PCDHA4 siRNA Set For knockdown and specificity verification in cell-based assays. |
View PCDHA4 Products |
| Related Target A | PCDHA1 Clustered alpha isoform; high sequence identity for counter-screening (ECD >95% similarity). |
View PCDHA1 Products |
| Related Target B | PCDHA5 Homologous cluster member for cross-reactivity counter-screening. |
View PCDHA5 Products |
| Related Target C | PCDHB1 Beta cluster paralog; off-target safety screening for distinct binding specificity. |
View PCDHB1 Products |
| Related Target D | PCDHGA1 Gamma-cluster protocadherin; parallel adhesive network for synaptic specificity studies. |
View PCDHGA1 Products |
| Related Target E | DNMT1 DNA methyltransferase modulating PCDHA4 epigenetic silencing. |
View DNMT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mammalian folding of cadherin EC repeats | HEK293 Expressed ECD-Fc; Native glycosylation; Sequence Verified; >95% purity |
| Isoform specificity within PCDHA cluster (A1–A12) | Homolog panel proteins (PCDHA1, PCDHA5, PCDHB1, PCDHGA1) strictly verified by mass spec |
| Cell surface presentation for binding/internalization | Lentivirus for stable cell line construction; full-length ORF preserves conformation |
| Lack of Controls | Benchmark Anti-PCDHA4 recombinant antibody included |
| False Positives / Off-target binding | Validated siRNA set for specificity checks and knockdown rescue |
| Cross-Species Cyno/Mouse Evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity; Endotoxin controlled for in vivo translation |
Live PCDHA4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Synaptic Biology Research
- ➤ Emerging Oncology Studies
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The research landscape for Protocadherin alpha-4 (PCDHA4) is emerging from foundational neurobiology into early-stage therapeutic and biomarker discovery. Currently dominated by academic research institutions exploring neurodevelopmental disorders (autism spectrum disorder, schizophrenia, epilepsy), emerging evidence linking protocadherin dysregulation to tumor microenvironments suggests potential oncology applications. PCDHA4 is heavily implicated in establishing precise neural circuitry and homophilic cell-cell adhesion; dysregulation—often via epigenetic silencing (e.g., DNMT1-mediated methylation)—is linked to neurological disorders and specific neuro-oncological indications. While targeted biologics for PCDHA4 remain in preclinical stages, the next wave of R&D is focused on utilizing its methylation patterns as liquid biopsy biomarkers, exploring its potential as a targeted surface antigen in aberrant tumor tissues, and advancing antibody-mediated blockade of homophilic interactions. The protein structure (three cadherin domains) and polymorphisms (rs11167605, rs3822346) offer additional handles for isoform-specific drug design.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Targeted Monoclonal Antibodies (Blocking mAb) | Academic Consortia, Early Biotech | Autism Spectrum Disorder, Synaptopathies, CNS Tumors | Homophilic Binding Inhibition (Need conformationally intact ECD-Fc); Isoform-specific binding assays |
| Soluble Decoy (ECD-Fc) | Neuroscience-focused Biotech | Neuronal Self-Avoidance Defects | High-Concentration Stability (Need aggregates-free protein for CSF-like conditions) |
| ADC | Oncology Exploratory Programs | Solid Tumors (PCDHα overexpression) | Internalization Assay (Need cell line with native membrane topology via Lentivirus) |
| Epigenetic Modulators (Small Mol) | Preclinical Discovery Phase | Neurodevelopmental Disorders | Cell-based Expression Assays (Need Lentivirus for Stable Cell Lines) |
| RNAi / ASO Therapies | Undisclosed Startups | Neuro-oncology | Knockdown Verification (Need Specific siRNA Sets & High-Affinity Abs) |
| Gene Therapy | Neurological Disease Foundations | Developmental Brain Disorders | Expression Validation (Need ORF-verified Lentivirus for transduction efficiency) |
Molecular Differentiation & Assay Strategy
Achieving best-in-class targeting of PCDHA4 requires overcoming extreme homology within the protocadherin family. Key strategies include:
- Epitope Selection: Target the unique non-conserved residues (likely in EC4–7 or juxtamembrane region) to avoid cross-reactivity with PCDHA1–13.
- Affinity Tuning: Moderate affinity (Kd 10–100 nM) suitable for dynamic synaptic regulation; measure on/off rates via SPR under pH 6.5–7.4.
- Mechanistic Assays: Cell aggregation assays using PCDHA4-Lentivirus stable cell lines for homophilic binding blockade; internalization assays for ADC feasibility.
- Cross-Species Validation: Human/Cyno/Mouse orthologs available for preclinical translation.
TarMart supports these with sequence-verified ECD-Fc proteins, homolog panels, lentivirus particles, and siRNA reagents.